257 related articles for article (PubMed ID: 30082489)
1. Pretreatment
Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a "PET biopsy" method.
Xie Y; Gu B; Hu X; Zhang Y; Zhang J; Wang Z; Zhao Y; Gong C; Li Y; Yang Z; Wang B
Cancer Manag Res; 2019; 11():6019-6027. PubMed ID: 31308743
[No Abstract] [Full Text] [Related]
3. Heterogeneity derived from
Xie Y; Liu C; Zhao Y; Gong C; Li Y; Hu S; Song S; Hu X; Yang Z; Wang B
Cancer Med; 2022 May; 11(9):1948-1955. PubMed ID: 35275444
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment
Ma G; You S; Xie Y; Gu B; Liu C; Hu X; Song S; Wang B; Yang Z
Cancer Imaging; 2023 Sep; 23(1):90. PubMed ID: 37726862
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer.
Li Y; Liu C; Wang B; Hu X; Gong C; Zhao Y; Xie Y; Zhang Y; Song S; Yang Z; Wang B
Int J Gen Med; 2021; 14():1797-1809. PubMed ID: 34007206
[TBL] [Abstract][Full Text] [Related]
6. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
7. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
8. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
9. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.
Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B
Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756
[TBL] [Abstract][Full Text] [Related]
10.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract][Full Text] [Related]
11. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
12. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
[TBL] [Abstract][Full Text] [Related]
13. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of early interim
Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment
Ma G; Gu B; Hu J; Kong L; Zhang J; Li Z; Xue Y; Lu J; Cao J; Cheng J; Zhang Y; Song S; Yang Z
Ann Nucl Med; 2021 Jul; 35(7):834-842. PubMed ID: 33913102
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract][Full Text] [Related]
18. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
[TBL] [Abstract][Full Text] [Related]
19. Harmonized pretreatment quantitative volume-based
Kitajima K; Miyoshi Y; Sekine T; Takei H; Ito K; Suto A; Kaida H; Daisaki H; Yamakado K
Hell J Nucl Med; 2020; 23(3):272-289. PubMed ID: 33367302
[TBL] [Abstract][Full Text] [Related]
20. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
